Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Axsome Therapeutics (AXSM) EBT Margin (2022 - 2025)

Axsome Therapeutics' EBT Margin history spans 4 years, with the latest figure at 14.35% for Q4 2025.

  • For Q4 2025, EBT Margin rose 4865.0% year-over-year to 14.35%; the TTM value through Dec 2025 reached 28.77%, up 4567.0%, while the annual FY2025 figure was 28.77%, 4567.0% up from the prior year.
  • EBT Margin for Q4 2025 was 14.35% at Axsome Therapeutics, up from 27.62% in the prior quarter.
  • Across five years, EBT Margin topped out at 9.13% in Q1 2023 and bottomed at 469.82% in Q2 2022.
  • The 4-year median for EBT Margin is 77.02% (2024), against an average of 110.92%.
  • The largest annual shift saw EBT Margin surged 32466bps in 2023 before it tumbled -8201bps in 2024.
  • A 4-year view of EBT Margin shows it stood at 251.29% in 2022, then skyrocketed by 45bps to 138.37% in 2023, then surged by 54bps to 63.0% in 2024, then surged by 77bps to 14.35% in 2025.
  • Per Business Quant, the three most recent readings for AXSM's EBT Margin are 14.35% (Q4 2025), 27.62% (Q3 2025), and 32.61% (Q2 2025).